Cullinan Therapeutics, Inc. (CGEM) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CGEM Revenue Growth
CGEM Revenue Analysis (2018–2025)
As of May 8, 2026, Cullinan Therapeutics, Inc. (CGEM) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, CGEM's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $18.9 million in 2021.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), RCUS (+67.4% YoY), and PRCT (+29.3% YoY). Compare CGEM vs KYMR →
CGEM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CGEMCurrent | $0 | - | - | - | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 PRCT | $308M | +29.3% | +109.0% | -33.7% |
CGEM Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-311,000 | - | $-241,648,000 | - |
| 2024 | $0 | - | $-306,000 | - | $-196,919,000 | - |
| 2023 | $0 | - | $0 | - | $-191,089,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $144.6M | - |
| 2021 | $18.9M | - | $18.9M | 100.0% | $-67,954,000 | -358.7% |
| 2020 | $0 | - | $-62,000 | - | $-60,335,000 | - |
| 2019 | $0 | - | $-70,000 | - | $-22,270,000 | - |
| 2018 | $0 | - | $-43,000 | - | $-14,586,000 | - |
See CGEM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGEM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGEM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCGEM — Frequently Asked Questions
Quick answers to the most common questions about buying CGEM stock.
Is CGEM's revenue growth accelerating or slowing?
CGEM TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CGEM's long-term revenue growth rate?
Cullinan Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CGEM's revenue distributed by segment?
CGEM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.